Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Azvudine (FNC), a next-generation cytidine analog with broad inhibitory activity against drug-resistant HIV-1 strains via stabilization of the reverse transcriptase catalytic complex.

Bioorganic chemistry·2026

Same author

Shortwave diathermy for managing knee osteoarthritis: A systematic review with meta-analysis.

Physiotherapy theory and practice·2026

Same author

Benzophenones exposure and precocious puberty in Chinese children: A case-control study.

Ecotoxicology and environmental safety·2026

Same author

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Nature medicine·2026

Same author

Tetrandrine-based in situ vaccination via multifunctional Mn²⁺-hyaluronic acid hydrogel loading gelatinase-responsive nanoparticles.

Journal of nanobiotechnology·2026

Same author

Trivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma.

Advanced healthcare materials·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Immunotherapy for Leiomyosarcoma: Current Status and Perspectives.

Haoyue Qi¹, Hanxi Zhang², Qin Wang²

¹Department of Oncology, Taikang Xianlin Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.

Journal of Immunology Research

|May 9, 2026

Summary

Leiomyosarcoma (LMS) treatment is challenging due to metastasis. This review explores immune microenvironment, gene expression, and molecular landscape to guide future therapies like immunotherapy and gene editing for better outcomes.

Keywords:

immunotherapy leiomyosarcoma soft-tissue sarcomas (STS)tumor microenvironment

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: May 11, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

Oncology
Immunotherapy
Genetics

Background:

Leiomyosarcoma (LMS), a type of soft-tissue sarcoma (STS), exhibits a high risk of distant metastasis.
Current first-line treatments for LMS yield unsatisfactory outcomes, making its management controversial and challenging.
There is a critical need to establish effective treatment strategies for LMS.

Purpose of the Study:

To analyze the immune microenvironment, gene expression, and molecular landscape of LMS.
To identify future research directions and prospects for LMS treatment.
To evaluate the potential of immunotherapies and gene editing technologies in managing LMS.

Main Methods:

Review of existing literature on LMS.
Analysis of immune microenvironment data.
Examination of gene expression patterns and molecular profiles.
Assessment of immunotherapy (e.g., immune checkpoint inhibitors) and gene editing technologies.

Main Results:

The immune microenvironment, gene expression, and molecular landscape offer insights into LMS biology.
Classical immunotherapy (immune checkpoint inhibitors) and novel approaches like cell therapy and gene editing show promise.
These advanced therapies may offer improved survival benefits and therapeutic mechanisms for LMS patients.

Conclusions:

Understanding LMS's molecular and immune characteristics is crucial for advancing treatment.
Immunotherapies and gene editing represent promising avenues for LMS management.
Further research and clinical application are needed to overcome challenges and realize the full potential of these therapies.